ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma

ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma

Abstract Background Multiple myeloma (MM) is an incurable hematological malignancy. Although proteasome inhibitors and immunomodulators have significantly improved patient outcomes, some patients respond poorly to treatment and almost all patients will relapse. Mechanisms of proteasome inhibitor res...

Full description

Bibliographic Details
Main Authors: Jifeng Jiang, Yifeng Sun, Jiadai Xu, Tianhong Xu, Zhao Xu, Peng Liu
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Cancer Medicine
Subjects:
multiple myeloma
NF‐κB
proteasome inhibitor resistance
ZHX2
Online Access:https://doi.org/10.1002/cam4.3347

Internet

https://doi.org/10.1002/cam4.3347

Similar Items